Skip to main content

Epileptic Encephalopathy

3
Pipeline Programs
5
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Neurocrine Biosciences
2 programs
2
NBI-827104Phase 21 trial
NBI-827104Phase 21 trial
Active Trials
NCT04625101Completed24Est. Oct 2022
NCT05301894Terminated19Est. Jan 2025
Servier
ServierFrance - Suresnes
1 program
1
S230815- Starting dose APhase 1/21 trial
Active Trials
NCT07227857Recruiting20Est. Apr 2028
Pins Medical
Pins MedicalChina - Beijing
1 program
PINS Vagus Nerve StimulatorN/A1 trial
Active Trials
NCT02603991Unknown1Est. Oct 2017
Precision BioSciences
1 program
1mg elsunersenPHASE_3RNA Therapeutic
Praxis Precision Medicines
1 program
1mg elsunersenPHASE_3RNA Therapeutic1 trial
Active Trials
NCT07019922Recruiting50Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Praxis Precision Medicines1mg elsunersen
Neurocrine BiosciencesNBI-827104
Neurocrine BiosciencesNBI-827104
ServierS230815- Starting dose A
Pins MedicalPINS Vagus Nerve Stimulator

Clinical Trials (5)

Total enrollment: 114 patients across 5 trials

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Start: Aug 2025Est. completion: Dec 202850 patients
Phase 3Recruiting

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Start: Jun 2022Est. completion: Jan 202519 patients
Phase 2Terminated

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Start: Apr 2021Est. completion: Oct 202224 patients
Phase 2Completed
NCT07227857ServierS230815- Starting dose A

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

Start: Nov 2025Est. completion: Apr 202820 patients
Phase 1/2Recruiting
NCT02603991Pins MedicalPINS Vagus Nerve Stimulator

Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE)

Start: Jun 2016Est. completion: Oct 20171 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 114 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.